CDC37 and gastrointestinal stromal tumor: Based on the evidence presented in this report, we believe that CK2/CDC37/KIT signalling is essential for GIST proliferation and survival, and that dual targeting of KIT and CK2 warrants evaluation as a novel therapeutic strategy in imatinib-sensitive and imatinib-resistant GIST.